Angel News
Angel News
Angel News

Back to Homepage

24th January 2017

24 January

BiVictriX Therapeutics (“BVX”) has today announced the completion of a successful fundraise to develop a new class of targeted cancer drugs. The company’s ‘Dual Targeting Approach’ is designed to give superior selectivity towards blood cancers. Acceleris Capital Ltd provided corporate finance advice to the Company.


Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:




Enter the characters in the image shown:

Back to Homepage